JP2010509356A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010509356A5 JP2010509356A5 JP2009536454A JP2009536454A JP2010509356A5 JP 2010509356 A5 JP2010509356 A5 JP 2010509356A5 JP 2009536454 A JP2009536454 A JP 2009536454A JP 2009536454 A JP2009536454 A JP 2009536454A JP 2010509356 A5 JP2010509356 A5 JP 2010509356A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrrolo
- pyridin
- substituted
- phenyl
- benzamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 9
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- -1 1- (4-fluorophenylsulfonyl) piperidin-4-yl Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 125000003107 substituted aryl group Chemical group 0.000 claims 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 4
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 3
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims 3
- 102000001253 Protein Kinases Human genes 0.000 claims 2
- 108060006633 Protein Kinases Proteins 0.000 claims 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 2
- 230000001772 anti-angiogenic Effects 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000035699 permeability Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000001603 reducing Effects 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- YBTMCZUJPRZRLP-UHFFFAOYSA-N 2-phenyl-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile Chemical compound C=1C2=CC(C#N)=CN=C2NC=1C1=CC=CC=C1 YBTMCZUJPRZRLP-UHFFFAOYSA-N 0.000 claims 1
- ASCDTBKWWRNRIU-UHFFFAOYSA-N 3-[(4-aminopiperidin-1-yl)methyl]-2-phenyl-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile Chemical compound C1CC(N)CCN1CC1=C(C=2C=CC=CC=2)NC2=NC=C(C#N)C=C12 ASCDTBKWWRNRIU-UHFFFAOYSA-N 0.000 claims 1
- VZFPCRAXOIAVPR-UHFFFAOYSA-N N-[3-(cyclopropylcarbamoyl)phenyl]-2-phenyl-1H-pyrrolo[2,3-b]pyridine-5-carboxamide Chemical compound C=1C=CC(NC(=O)C=2C=C3C=C(NC3=NC=2)C=2C=CC=CC=2)=CC=1C(=O)NC1CC1 VZFPCRAXOIAVPR-UHFFFAOYSA-N 0.000 claims 1
- YSQYCEMHQTZHHG-UHFFFAOYSA-N N-cyclopropyl-2,4-difluoro-5-[(2-phenyl-1H-pyrrolo[2,3-b]pyridin-5-yl)methylamino]benzamide Chemical compound FC1=CC(F)=C(C(=O)NC2CC2)C=C1NCC(C=C1C=2)=CN=C1NC=2C1=CC=CC=C1 YSQYCEMHQTZHHG-UHFFFAOYSA-N 0.000 claims 1
- NPDNQMAHTBBMTM-UHFFFAOYSA-N N-cyclopropyl-3-[(2-cyclopropyl-1H-pyrrolo[2,3-b]pyridin-5-yl)methylamino]-4-fluorobenzamide Chemical compound FC1=CC=C(C(=O)NC2CC2)C=C1NCC(C=C1C=2)=CN=C1NC=2C1CC1 NPDNQMAHTBBMTM-UHFFFAOYSA-N 0.000 claims 1
- NBUUNYHOCCNNIV-UHFFFAOYSA-N N-cyclopropyl-3-[[2-[3-[2-(dimethylamino)ethoxy]phenyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]methylamino]-4-fluorobenzamide Chemical compound CN(C)CCOC1=CC=CC(C=2NC3=NC=C(CNC=4C(=CC=C(C=4)C(=O)NC4CC4)F)C=C3C=2)=C1 NBUUNYHOCCNNIV-UHFFFAOYSA-N 0.000 claims 1
- ZFBNPNOJLQAKNS-UHFFFAOYSA-N N-cyclopropyl-4-fluoro-3-[(2-phenyl-1H-pyrrolo[2,3-b]pyridin-5-yl)methylamino]benzamide Chemical compound FC1=CC=C(C(=O)NC2CC2)C=C1NCC(C=C1C=2)=CN=C1NC=2C1=CC=CC=C1 ZFBNPNOJLQAKNS-UHFFFAOYSA-N 0.000 claims 1
- ZGILBHDPGVMKEC-UHFFFAOYSA-N N-cyclopropyl-4-fluoro-3-[[2-(4-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]methylamino]benzamide Chemical compound C1=CC(OC)=CC=C1C1=CC2=CC(CNC=3C(=CC=C(C=3)C(=O)NC3CC3)F)=CN=C2N1 ZGILBHDPGVMKEC-UHFFFAOYSA-N 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 210000003802 Sputum Anatomy 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000006448 cycloalkyl cycloalkyl group Chemical group 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000005349 heteroarylcycloalkyl group Chemical group 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 150000002829 nitrogen Chemical group 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 230000002062 proliferating Effects 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
Claims (12)
- 式(I):
XおよびYは独立して、−CH2−、−NH−、−S−、もしくは−O−であり、またはXおよびYの一方は存在せず;
R1、R2およびR3は独立して、水素、アルキル、置換アルキル、シクロアルキル、置換シクロアルキル、アリール、置換アリール、ヘテロアリール、置換ヘテロアリール、ヘテロシクロアルキル、置換ヘテロシクロアルキル、アリールオキシ、または置換アリールオキシであり;
R4およびR5は独立して、水素、アルキル、置換アルキル、アリール、置換アリール、シクロアルキル、置換シクロアルキル、ヘテロシクリル、または置換ヘテロシクリルであるか、あるいは
R4およびR5は、それらが結合している窒素原子とともに、一緒になって適宜置換されるヘテロシクリル環を形成し;
R6は独立して、一またはそれ以上の水素、アルキル、置換アルキル、アリール、置換アリール、シアノまたはハロゲンである]
の化合物、またはその医薬的に許容される塩、または立体異性体。 - Xが−CH2−、Yが −NH−であるか、またはXおよびYの一方が存在せず、他方が−O−もしくは−S−であり;
R1、R2およびR3が独立して、水素、アリール、置換アリール、ヘテロアリール、置換ヘテロアリール、シクロアルキル、または置換シクロアルキルであり;並びに
R4およびR5が独立して、水素、シクロアルキル、置換シクロアルキル、ヘテロシクリル、または置換ヘテロシクリルである、請求項1の化合物、
またはその医薬的に許容される塩、または立体異性体。 - N−シクロプロピル−4−フルオロ−3−{(2−フェニル−1H−ピロロ[2,3−b]ピリジン−5−イル)メチルアミノ}ベンズアミド、
N−シクロプロピル−2,4−ジフルオロ−5−((2−フェニル−1H−ピロロ[2,3−b]ピリジン−5−イル)メチルアミノ)ベンズアミド、
N−シクロプロピル−4−フルオロ−3−((2−フェニル−1H−ピロロ[2,3−b]ピリジン−5−イルアミノ)メチル)ベンズアミド、
N−シクロプロピル−3−((2−シクロプロピル−1H−ピロロ[2,3−b]ピリジン−5−イル)メチルアミノ)−4−フルオロベンズアミド、
N−シクロプロピル−4−フルオロ−3−((2−(ピリジン−3−イル)−1H−ピロロ[2,3−b]ピリジン−5−イル)メチルアミノ)ベンズアミド、
N−シクロプロピル−4−フルオロ−3−((2−(ピリジン−2−イル)−1H−ピロロ[2,3−b]ピリジン−5−イル)メチルアミノ)ベンズアミド、
N−シクロプロピル−4−フルオロ−3−((2−(4−メトキシフェニル)−1H−ピロロ[2,3−b]ピリジン−5−イル)メチルアミノ)ベンズアミド、
N−シクロプロピル−3−((2−(3−(2−(ジメチルアミノ)エトキシ)フェニル)−1H−ピロロ[2,3−b]ピリジン−5−イル)メチルアミノ)−4−フルオロベンズアミド、
N−(1−(4−フルオロフェニルスルホニル)ピペリジン−4−イル)−3−(2−フェニル−1H−ピロロ[2,3−b]ピリジン−5−イルオキシ)ベンズアミド、
N−(1−(4−フルオロフェニルスルホニル)アゼチジン−3−イル)−3−(2−フェニル−1H−ピロロ[2,3−b]ピリジン−5−イルオキシ)ベンズアミド、
N−(1−(4−フルオロフェニルスルホニル)アゼチジン−3−イル)−3−(2−フェニル−1H−ピロロ[2,3−b]ピリジン−5−イルチオ)ベンズアミド、
N−(1−(4−フルオロフェニルスルホニル)ピペリジン−4−イル)−3−(2−フェニル−1H−ピロロ[2,3−b]ピリジン−5−イルチオ)ベンズアミド、
N−(3−(シクロプロピルカルバモイル)フェニル)−2−フェニル−1H−ピロロ[2,3−b]ピリジン−5−カルボキサミド、
2−フェニル−1H−ピロロ[2,3−b]ピリジン−5−カルボニトリル、
3−((4−アミノピペリジン−1−イル)メチル)−2−フェニル−1H−ピロロ[2,3−b]ピリジン−5−カルボニトリル;
からなる群から選択される化合物、またはその医薬的に許容される塩、または立体異性体。 - 請求項1の化合物の一またはそれ以上、および医薬的に許容される担体を含む医薬組成物。
- 請求項1の化合物の一またはそれ以上を、医薬的に許容される担体、および一またはそれ以上の他の抗癌剤もしくは細胞毒性薬と組み合わせて含む医薬組成物。
- 請求項1の化合物の一またはそれ以上の有効な抗血管新生産生量を含む、抗血管新生効果を産出する薬剤。
- 請求項1の化合物の一またはそれ以上の有効な血管透過性減少効果量を含む、血管透過性減少効果を産出する薬剤。
- 請求項1の化合物の一またはそれ以上の有効なプロテインキナーゼ阻害量を含む、成長因子受容体のプロテインキナーゼ活性阻害剤。
- 請求項1の化合物の一またはそれ以上の有効なチロシンキナーゼ阻害量を含む、成長因子受容体のチロシンキナーゼ活性阻害剤。
- 請求項4の組成物の治療上の有効量を含む、増殖性疾患治療剤。
- 請求項4の組成物の治療上の有効量を含む、癌治療剤。
- 請求項1の化合物の一またはそれ以上の治療上の有効量を含む、成長因子受容体を通じて作動するシグナル伝達経路に関係する疾患の治療剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86518106P | 2006-11-10 | 2006-11-10 | |
US60/865,181 | 2006-11-10 | ||
PCT/US2007/083850 WO2008060907A2 (en) | 2006-11-10 | 2007-11-07 | Pyrrolo-pyridine kinase inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2010509356A JP2010509356A (ja) | 2010-03-25 |
JP2010509356A5 true JP2010509356A5 (ja) | 2010-10-21 |
JP5244118B2 JP5244118B2 (ja) | 2013-07-24 |
Family
ID=39261598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009536454A Expired - Fee Related JP5244118B2 (ja) | 2006-11-10 | 2007-11-07 | 新規キナーゼ阻害剤 |
Country Status (6)
Country | Link |
---|---|
US (1) | US8148361B2 (ja) |
EP (1) | EP2081928B1 (ja) |
JP (1) | JP5244118B2 (ja) |
CN (1) | CN101600714B (ja) |
NO (1) | NO20091708L (ja) |
WO (1) | WO2008060907A2 (ja) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5702293B2 (ja) | 2008-11-10 | 2015-04-15 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Atrキナーゼの阻害剤として有用な化合物 |
MX2011006503A (es) | 2008-12-19 | 2011-09-06 | Vertex Pharma | Derivados de pirazina utiles como inhibidores de la cinasa de atr. |
FR2941948B1 (fr) * | 2009-02-12 | 2013-04-05 | Nova Decision | Derives d'azaindoles en tant qu'inhibiteur des proteines kinases abl et src |
AU2010232729A1 (en) | 2009-03-31 | 2011-10-20 | Arqule, Inc. | Substituted indolo-pyridinone compounds |
AU2011218190A1 (en) * | 2010-02-17 | 2012-09-06 | Janssen Pharmaceutica Nv | Aminothiazolones as estrogen related receptor-alpha modulators |
GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
EP2569289A1 (en) | 2010-05-12 | 2013-03-20 | Vertex Pharmaceuticals Incorporated | Pyrazines useful as inhibitors of atr kinase |
WO2011143425A2 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
WO2011143423A2 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
SG185524A1 (en) | 2010-05-12 | 2012-12-28 | Vertex Pharma | Compounds useful as inhibitors of atr kinase |
CA2798760A1 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | 2-aminopyridine derivatives useful as inhibitors of atr kinase |
WO2011143399A1 (en) * | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
CA2803802A1 (en) | 2010-06-23 | 2011-12-29 | Vertex Pharmaceuticals Incorporated | Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase |
US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
CA2832100A1 (en) | 2011-04-05 | 2012-10-11 | Vertex Pharmaceuticals Incorporated | Aminopyrazine compounds useful as inhibitors of tra kinase |
US9309250B2 (en) | 2011-06-22 | 2016-04-12 | Vertex Pharmaceuticals Incorporated | Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors |
WO2012178124A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
WO2012178123A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
MX353461B (es) | 2011-09-30 | 2018-01-15 | Vertex Pharma | PROCESOS PARA PREPARAR COMPUESTOS ÚTILES COMO INHIBIDORES DE CINASA ATAXIA TELANGIECTASIA MUTADA Y Rad3 RELACIONADOS (ATR). |
US8853217B2 (en) | 2011-09-30 | 2014-10-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
KR102056586B1 (ko) | 2011-09-30 | 2019-12-18 | 버텍스 파마슈티칼스 인코포레이티드 | Atr 억제제를 이용한 췌장암 및 비소세포 폐암의 치료 |
CA2850564A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
EP2751088B1 (en) | 2011-09-30 | 2016-04-13 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
EP2776419B1 (en) | 2011-11-09 | 2016-05-11 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
US8841337B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
WO2013071088A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
WO2013071093A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
US8846918B2 (en) | 2011-11-09 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
CA2869309C (en) | 2012-04-05 | 2021-02-09 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase and combination therapies thereof |
PT3176170T (pt) | 2012-06-13 | 2019-02-05 | Incyte Holdings Corp | Compostos tricíclicos substituídos como inibidores de fgfr |
WO2014026125A1 (en) * | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
WO2014048878A1 (en) * | 2012-09-26 | 2014-04-03 | Evotec (Uk) Ltd. | Phenyl- or pyridyl- pyrrolo[2,3b]pyrazine derivatives useful in the treatment or prevention of proliferative disorders or dysplasia |
US8999632B2 (en) | 2012-10-04 | 2015-04-07 | Vertex Pharmaceuticals Incorporated | Method for measuring ATR inhibition mediated increases in DNA damage |
US8912198B2 (en) | 2012-10-16 | 2014-12-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
HUE055618T2 (hu) | 2012-12-07 | 2021-12-28 | Vertex Pharma | 2-amino-N-(piperidin-1-il-piridin-3-il)-pirazolo-[1,5-alfa]-pirimidin-3-karboxamid, mint atr-kináz inhibítoraként használható vegyület |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
FR3000492B1 (fr) * | 2012-12-28 | 2015-09-11 | Oribase Pharma | Nouveaux derives azaindole en tant qu'inhibiteurs multikinases |
FR3000493A1 (fr) * | 2012-12-28 | 2014-07-04 | Oribase Pharma | Nouveaux inhibiteurs de proteines kinases |
EP2970286A1 (en) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Inc. | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
WO2014139145A1 (en) * | 2013-03-15 | 2014-09-18 | Hutchison Medipharma Limited | Novel pyrimidine and pyridine compounds and usage thereof |
SG10201708520YA (en) | 2013-04-19 | 2017-12-28 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
CA2932757C (en) | 2013-12-06 | 2023-10-31 | Vertex Pharmaceuticals Incorporated | 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof |
KR102479693B1 (ko) | 2014-03-26 | 2022-12-22 | 아스텍스 테라퓨틱스 리미티드 | 조합물 |
WO2015144808A1 (en) | 2014-03-26 | 2015-10-01 | Astex Therapeutics Ltd | Combinations of an fgfr inhibitor and an igf1r inhibitor |
RU2020110358A (ru) | 2014-06-05 | 2020-04-30 | Вертекс Фармасьютикалз Инкорпорейтед | Радиоактивно меченные производные 2-амино-6-фтор-n-[5-фтор- пиридин-3-ил]-пиразоло[1,5-а]пиримидин-3-карбоксамида, используемые в качестве ингибитора atr киназы, препараты на основе этого соединения и его различные твердые формы |
DK3157566T3 (da) | 2014-06-17 | 2019-07-22 | Vertex Pharma | Fremgangsmåde til behandling af cancer under anvendelse af en kombination chk1- og atr-inhibitorer |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
TWI712601B (zh) | 2015-02-20 | 2020-12-11 | 美商英塞特公司 | 作為fgfr抑制劑之雙環雜環 |
WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
RU2768621C1 (ru) | 2015-09-30 | 2022-03-24 | Вертекс Фармасьютикалз Инкорпорейтед | Способ лечения рака с использованием комбинации повреждающих днк средств и ингибиторов atr |
PL3362449T3 (pl) * | 2015-10-13 | 2021-12-13 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Pochodne sybiriliny do zastosowania do zapobiegania i/lub leczenia zaburzeń związanych z nekroptozą komórkową |
CN108570052A (zh) * | 2017-03-13 | 2018-09-25 | 中国科学院上海药物研究所 | 五元杂环并吡嗪化合物、制备方法、中间体、组合和应用 |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
MA52493A (fr) | 2018-05-04 | 2021-03-10 | Incyte Corp | Sels d'un inhibiteur de fgfr |
US11466004B2 (en) | 2018-05-04 | 2022-10-11 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
WO2020264420A1 (en) * | 2019-06-28 | 2020-12-30 | Gb002, Inc. | Heterocyclic kinase inhibitors and products and uses thereof |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
CA3157361A1 (en) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
JP2023505258A (ja) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Fgfr阻害剤としての三環式複素環 |
BR112022010664A2 (pt) | 2019-12-04 | 2022-08-16 | Incyte Corp | Derivados de um inibidor de fgfr |
EP4352059A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6335342B1 (en) * | 2000-06-19 | 2002-01-01 | Pharmacia & Upjohn S.P.A. | Azaindole derivatives, process for their preparation, and their use as antitumor agents |
TW200400034A (en) | 2002-05-20 | 2004-01-01 | Bristol Myers Squibb Co | Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors |
TW200401638A (en) | 2002-06-20 | 2004-02-01 | Bristol Myers Squibb Co | Heterocyclic inhibitors of kinases |
MX2007001127A (es) | 2004-07-27 | 2007-07-11 | Sgx Pharmaceuticals Inc | Moduladores de pirrolo-piridina cinasa. |
EP1881983B1 (en) * | 2005-05-20 | 2012-01-11 | Vertex Pharmaceuticals, Inc. | Pyrrolopyridines useful as inhibitors of protein kinase |
-
2007
- 2007-11-07 JP JP2009536454A patent/JP5244118B2/ja not_active Expired - Fee Related
- 2007-11-07 EP EP07844925.3A patent/EP2081928B1/en active Active
- 2007-11-07 US US12/513,928 patent/US8148361B2/en active Active
- 2007-11-07 WO PCT/US2007/083850 patent/WO2008060907A2/en active Application Filing
- 2007-11-07 CN CN2007800496931A patent/CN101600714B/zh not_active Expired - Fee Related
-
2009
- 2009-04-29 NO NO20091708A patent/NO20091708L/no not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010509356A5 (ja) | ||
JP2007505877A5 (ja) | ||
JP2007517807A5 (ja) | ||
JP2013510120A5 (ja) | ||
JP6021805B2 (ja) | 腫瘍治療剤 | |
JP2008517913A5 (ja) | ||
JP2004516314A5 (ja) | ||
JP2009536620A5 (ja) | ||
JP2009504764A5 (ja) | ||
JP2009504763A5 (ja) | ||
JP2009501745A5 (ja) | ||
JP2008530099A5 (ja) | ||
JP2020523388A5 (ja) | ||
JP2018168191A5 (ja) | ||
JP2010523556A5 (ja) | ||
JP2014508811A5 (ja) | ||
JP2010504344A5 (ja) | ||
JP2019518770A5 (ja) | ||
JP2012508249A5 (ja) | ||
JP2010527985A5 (ja) | ||
UA93687C2 (en) | N-(heteroaryl)-1-heteroarylalkyl-1h-indole-2-carboxamide derivatives, preparation and therapeutic use thereof | |
JP2006523193A5 (ja) | ||
JP2012509263A5 (ja) | ||
JP2011509302A5 (ja) | ||
JP2017525717A5 (ja) |